Alkem Laboratories Limited (ALKEM)
🎯 Key Takeaways
- Alkem Laboratories is in a phase of strategic consolidation and margin expansion within its pharmaceutical portfolio, leveraging strong profitability in chronic therapies and biosimilars to drive sustainable growth. Management is actively integrating acquired assets like Occlutech and aligning capital structure with long-term value creation, supported by consistent cash generation and disciplined capital allocation.
- Revenue declined 3.6% QoQ to ₹3,603 in Q4FY26.
- ⚠️ Margin pressure in Q4FY26 (OPM at 14.4%) may signal execution risks in sustaining high profitability amid competitive pricing or input cost volatility
📖 The Story
Alkem Laboratories is in a phase of strategic consolidation and margin expansion within its pharmaceutical portfolio, leveraging strong profitability in chronic therapies and biosimilars to drive sustainable growth. Management is actively integrating acquired assets like Occlutech and aligning capital structure with long-term value creation, supported by consistent cash generation and disciplined capital allocation.
📰 What's Happening
In FY26, Alkem reported record revenue of ₹3,052 crores (+13.5% YoY) and EBITDA of ₹3,000+ crores (+19.6%), driven by robust performance in chronic therapies and GLP-1 semaglutide capturing 11% market share. The company completed the acquisition of 79,36,50,794 shares in Alkem Medtech for Rs. 11,00,00,00,005, securing control of Alkem Medtech to expand into medical devices. Shareholders are set to vote on August 17, 2026, on the amalgamation of Adroit Biomed, its wholly owned subsidiary, under NCLT supervision, requiring a 75% majority in value via remote e-voting from August 12-16. Management projects FY27 tax rates of 27-29% and margin expansion to 20-21%, with Occlutech integration expected within 45-60 days.
Source: Stock Announcements
📊 Quarterly Results (₹ Cr)
| Metric | Q1FY25 | Q2FY25 | Q3FY25 | Q4FY25 | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 3,032 | 3,415 | 3,374 | 3,144 | 3,371 | 4,001 | 3,737 | 3,603 |
| Operating Profit | 729 | 887 | 852 | 537 | 888 | 1,024 | 918 | 582 |
| OPM % | 20.1% | 22.1% | 22.5% | 12.4% | 21.9% | 23.0% | 22.2% | 14.4% |
| Net Profit | 550 | 702 | 641 | 322 | 668 | 779 | 653 | 251 |
| EPS | ₹45.60 | ₹57.60 | ₹52.34 | ₹25.57 | ₹55.56 | ₹63.99 | ₹53.19 | ₹19.77 |
Quarterly revenue has shown a clear upward trend, rising from ₹3,032 crores in Q1FY25 to ₹3,603 crores in Q4FY26, reflecting consistent top-line growth. However, operating profit and margins have exhibited volatility, peaking at 23.0% in Q2FY26 before declining to 14.4% in Q4FY26, indicating possible seasonality or cost pressures. Net profit peaked at ₹779 crores in Q2FY26 but moderated to ₹251 crores in Q4FY26, suggesting earnings normalization. Despite this, EBITDA margin expansion to 20.4% in FY26 and management’s guidance of 20-21% for FY27 signal confidence in sustained profitability improvement, supported by operational efficiencies and strategic initiatives.
🔮 Management Outlook & What's Next
Management has provided forward-looking guidance on FY27 tax rates (27-29%) and EBITDA margins (20-21%), underscoring expectations of continued margin expansion. Integration of Occlutech is expected within 45-60 days, and the company maintains a stable dividend payout ratio of 25-30%. These projections are tied to strategic focus on chronic therapies, biosimilars, and medical device expansion, with no share buybacks or major capital returns planned beyond regular dividends.
Extracted from official company announcements. Not StockFin.ai's opinion.
🏦 Balance Sheet (₹ Cr)
| Item | 2024-2025 | 2025-2026 | 2025-2026 | 2025-2026 | 2025-2026 |
|---|---|---|---|---|---|
| Equity Capital | 24 | 24 | 24 | 24 | 24 |
| Reserves | 11,961 | — | 13,322 | — | 13,796 |
| Borrowings | 1,063 | — | 1,962 | — | 1,624 |
| Total Liabilities | 5,257 | — | 6,477 | — | 6,524 |
| Fixed Assets | 2,064 | — | 2,111 | — | 2,695 |
| Investments | 1,846 | — | 2,533 | — | 1,869 |
| Total Assets | 17,691 | — | 20,287 | — | 20,873 |
The balance sheet reflects a conservative capital structure with low debt-to-equity (0.09) and manageable net borrowings of ₹1,624 crores, enabling financial flexibility. Equity and reserves have remained stable, supporting reinvestment in growth areas like Alkem Medtech and Adroit Biomed. The company is not over-leveraged, and capital allocation appears focused on strategic acquisitions and integration rather than aggressive shareholder distributions, aligning with long-term stability.
💰 Cash Flow Statement (₹ Cr)
| Item | 2020-2021 |
|---|---|
| Operating | +776 |
| Investing | -534 |
| Financing | -246 |
| Net Cash Flow | — |
⚖️ Peer Comparison — Pharmaceuticals & Biotechnology
| Company | MCap (₹ Cr) | P/E | ROCE | ROE | D/E |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | 4.51 L Cr | 41.3 | 20.3% | 15.1% | 0.03 |
| Divi's Laboratories Limited | 1.79 L Cr | 72.4 | 22.1% | 16.6% | 0.00 |
| Torrent Pharmaceuticals Limited | 1.49 L Cr | 80.1 | — | — | — |
| Cipla Limited | 1.16 L Cr | 25.4 | 19.4% | 14.6% | 0.00 |
| Dr. Reddy's Laboratories Limited | 1.12 L Cr | 20.0 | 19.7% | 16.6% | 0.12 |
| Lupin Limited | 1.04 L Cr | 36.2 | — | — | — |
| Mankind Pharma Limited | 1.03 L Cr | 49.2 | — | — | — |
| Zydus Lifesciences Limited | 1.02 L Cr | 22.5 | — | — | — |
| Aurobindo Pharma Limited | 87,806 | 25.3 | — | — | — |
| Laurus Labs Limited | 71,455 | 356.8 | — | — | — |
🔗 Peer Stock Analyses
⚠️ Risk Factors
1. Margin pressure in Q4FY26 (OPM at 14.4%) may signal execution risks in sustaining high profitability amid competitive pricing or input cost volatility. 2. Integration of Alkem Medtech and Adroit Biomed carries execution and regulatory risks, with NCLT and SEBI approvals still pending. 3. Dependence on GLP-1 semaglutide and chronic therapy demand introduces commercial risk if market dynamics shift. 4. Forex volatility remains a concern, though 80% hedging provides partial protection, requiring continued active management.
📋 Recent Filings
-
🟡 related party transaction 16 July 2026Alkem Laboratories announced it acquired 79,36,50,794 equity shares in Alkem Medtech Private Limited at Rs. 13.86 per share for a total consideration ...
-
🔴 Corporate Action 15 July 2026Alkem Laboratories announced a shareholders' meeting on August 17, 2026, to approve a scheme of amalgamation with Adroit Biomed Limited, its wholly ow...
-
Announcement 1 July 2026Alkem Laboratories disclosed favorable tax appeal orders from the Commissioner of Income Tax (Appeals) for assessment years 2018-19 to 2022-23, deleti...
-
Announcement 29 June 2026Alkem Laboratories announced an upcoming analyst and institutional investor meeting scheduled for July 6, 2026, in Mumbai, to discuss its business out...
-
Announcement 29 June 2026Alkem Laboratories announced that its wholly owned subsidiary Alkem Medtech executed a First Supplementary Agreement to the Share Purchase Agreement f...
-
Financial Results 24 June 2026Alkem Laboratories has announced that its trading window will close on 29 June 2026 and remain closed for 48 hours after the quarterly results for the...
-
Announcement 15 June 2026Alkem Laboratories announced its upcoming analyst and institutional investor meeting schedule on June 19, 2026, conducted virtually with Millennium Ma...
-
Announcement 10 June 2026Alkem Laboratories announced its upcoming analyst and institutional investor meeting scheduled for June 16, 2026, in Mumbai, inviting one-on-one sessi...
-
Announcement 2 June 2026Alkem Laboratories announced it is India's first to launch semaglutide in single-shot pre-filled syringes priced starting at INR350, expanding patient...
-
🔴 Financial Results 1 June 2026Alkem Laboratories reported FY26 revenue growth of 13.5% to INR3,052 crores, driven by 19.6% EBITDA growth to INR3,000+ crores and a 20.4% margin, wit...
🧠 Analyst's Read
Alkem Laboratories is executing a disciplined growth strategy with strong profitability and strategic acquisitions, but near-term margin volatility and regulatory dependencies require monitoring. Investors should watch for successful Occlutech integration, progress on the Adroit Biomed merger, and sustained margin expansion in FY27 to confirm the trajectory.
Based on filing content and financial data. Not a recommendation.
Read the full analysis
Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.
Sign Up Free — Unlock Full Analysis2 free AI queries per day.
Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-07-16.
📡 Get AI alerts when ALKEM files new disclosures
Track ALKEM filings, board meetings, and corporate actions. Free email alerts at 5 PM.
Track ALKEM — FreeFree account · 2 AI queries/day
© 2026 StockFin.ai — AI-powered Indian stock research